Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + eribulin mesylate + paclitaxel
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three distinct anticancer drugs used in breast cancer treatment. Doxorubicin is an anthracycline antibiotic that works by intercalating DNA and generating reactive oxygen species. Eribulin mesylate is a synthetic analog of halichondrin B that inhibits microtubule dynamics. Paclitaxel is a taxane that stabilizes microtubules and prevents cell division. This combination may be used sequentially rather than simultaneously in breast cancer treatment protocols.
02
Targets
MicrotubuleDNA
Beyond the preview
Go deeper on doxorubicin + eribulin mesylate + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + eribulin mesylate + paclitaxel.